HRAS and head and neck squamous cell carcinoma: In addition, a clear distinction between these HNSCC cells was that cleaved caspase-3 was significantly increased by the combination therapy in Detroit 562 (PIK3CA mutant) but not in UM-SCC-17B (HRAS mutant) (Figure 4C).